2018 esc/eacts guidelines on myocardial revascularization ... · benedetto umberto nothing to be...

Ahlsson Anders 1- Financial Declaration

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Sanofi Aventis : Atrial fibrillation symposium speakers fee year 2008: 500 Euro (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Swedish Society of Medicine : Financial support for studies (2016-2017)

- Örebro university hospital Research committee : Financial support for studies years 2008-2013 (2016-2017)

- Vingmed / Estech : Microwave ablation study year 2008: 5000 Euro (2016-2017)

Alfonso Manterola Fernando

Nothing to be declared (2016-2017)

Banning Adrian Paul 1- Financial Declaration


- Boston Scientific : coronary stents (2016)

- Medtronic : coronary stents (2016)

- Abbott Vascular : coronary stents (2016)

- Philips : intravascular ultrasound (2016)

- Miracor : PICSO (2016)

- Philips : IVUS (2017)

- Abbott : stents (2017)

- Boston Scientific : stents (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : interventional research (2016)

- Boston Scientific : stents (2017)

24/08/2018

2018 ESC/EACTS Guidelines on myocardial revascularization - Task Force

Expert Type of Relationship with Industry

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

1/54

Benedetto Umberto


Byrne Robert 1- Financial Declaration


- Boston Scientific : Vascular intervention (2016-2017)

- Biotronik : Vascular intervention (2016-2017)

- B.Braun : Vascular intervention (2016-2017)

- Micell Technologies : Vascular intervention (2017)

D - Research funding (departmental or institutional) from healthcare industry.- HeartFlow : Imaging analysis (2016)

- Boston Scientific : Vascular intervention (2016-2017)

- Celonova : Vascular intervention (2017)

Collet Jean-Philippe 1- Financial Declaration


- BMS : apixaban (2016)

- Sanofi Aventis : CLOPIDOGREL (2016)

- Medtronic : corevalve (2016)

- Eli Lilly : PRASUGREL (2016)

- Astra-Zeneca : ticagrelor (2016)

- MSD : VORAPAXAR (2016)

- Bayer Healthcare : xarelto (2016)

- Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017)

24/08/2018




2/54

Collet Jean-Philippe - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017)

- Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017)

- Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bristol Myers Squibb : APIXABAN (2016)

- Medtronic : COREVALVE (2016)

- Stago : LABORATORY TEST (2016)


- FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)

- ICAN : THROMBOSIS (2016)

- Astra Zeneca : TICAGRELOR (2016)

- Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017)

- Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017)

- Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017)

- Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

- Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

Falk Volkmar 1- Financial Declaration


- Dr. Falk reports grants and other from Abbott, grants and other from Medtronic, grants and other from Edwards, outside the submitted work; and Advisory board: : Educational Grant and other (2017)

24/08/2018




3/54

Falk Volkmar B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Boston Scientific : heart valves (2016)

- Edwards Lifesciences : heart valves (2016)

- Medtronic : heart valves (2016)

- Aesculap : minimally invasive mitral surgery (2016)

D - Research funding (departmental or institutional) from healthcare industry.- Philips : Imaging (2016)

- Heartware : LVAD (2016)

- SJM : VAD Therapy (2016)

Head Stuart

Nothing to be declared (2017)

1- Financial Declaration


- medistim : Graft flow measurement (2016)

Juni Peter



D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : Anti-platelet Therapy (2017)

- Biotronik : Drug-eluting stents (2017)

- Biosensors International Group : Drug-eluting stents (2017)

- The Medicines Company : Thrombin inhibitors (2017)

24/08/2018




4/54

Juni Peter 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly

and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

Kastrati Adnan 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- I have benefitted licence fees related to own patents on drug-eluting stents (2016)

- I have benefitted licence fees related to own patents on drug-eluting stents. (2017)

Koller Akos


Kristensen Steen Dalby 1- Financial Declaration


- Aspen : anti-thrombotics fondaparinux (2016)

- Bayer AG : anti-thrombotics rivaroxiban (2016)

- Astra Zeneca : anti-thrombotics Ticagrelor (2016)

- BMS/Pfizer : apixaban (2017)

- Bayer : rivaroxiban (2017)

- Astra Zeneca : ticagrelor (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : ticagrelor (2016)

Neumann Franz Josef 1- Financial Declaration

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Boehringer-Ingelheim : Anticoagulant Therapy (2016-2017)

24/08/2018




5/54

Neumann Franz Josef - Daiichi Sankyo : Anticoagulant therapy (2016-2017)

- Pfizer : Anticoagulant therapy (2016-2017)

- Bayer Healthcare : Anticoagulant therapy (2016-2017)

- Bristol Myers Squibb : Anticoagulant therapy (2016-2017)

- Astra Zeneca : Antiplatelet therapy (2016-2017)

- Boston Scientific : Interventional cardiology (2016-2017)

- Edwards Lifesciences : Transcatheter valves (2016-2017)

- Medtronic : Transcatheter valves (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bayer Healthcare : Anticoagulant therapy (2016-2017)

- Novartis : Heart failure (2016-2017)

- Pfizer : Heart failure (2016-2017)

- GlaxoSmithKline : Heart failure (2016-2017)

- Biotronik : Interventional Cardiology (2016-2017)

- Abbott Vascular : MitraClip (2016-2017)

- Edwards Lifesciences : Transcatheter Valves (2016-2017)

- Medtronic : Transcatheter Valves (2016-2017)

Niebauer Josef




- Novartis : cardio-metabolic (2017)

24/08/2018




6/54

Richter Dimitrios 1- Financial Declaration


- Angelini : Lipids (2016)

- Swisspharma : lipids-hypertension (2016)

- Astra Zeneca : lipids-thrombosis (2016)

- Pfizer : lipids-thrombosis (2016)

- Winmedica : lipids-thrombosis (2016)

- Boehringer-Ingelheim : thrombosis (2016)

- Menarini : CAD- hypertension (2016-2017)

- Novartis : hypertension (2016-2017)

- Abbott : lipids (2016-2017)

- Amgen : lipids (2016-2017)

- Sanofi Aventis : Lipids (2016-2017)

- Lilly : Lipids (2016-2017)

- Unilever : lipids (2016-2017)

- Merck Sharp & Dohme : lipids (2016-2017)

- Vianex : lipids (2016-2017)

- Galenica : Lipids (2016-2017)

- Teva Pharmaceutical Industries : lipids, hypertension (2016-2017)

- Bayer Healthcare : Thrombosis (2016-2017)

- Edwards Lifesciences : aortic stenosis (2017)

24/08/2018




7/54

Richter Dimitrios - Novo-Nordisk : diabetes (2017)

- Unipharma : hypertension-thrombosis (2017)

Seferovic Petar 1- Financial Declaration


- Servier : coronary disease, heart failure (2016-2017)

- Boehringer-Ingelheim : heart failure, hypertension (2016-2017)

- Pfizer : heart failure, hypertension (2016-2017)

- Berlin Chemie AG : heart failure, hypertension (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Ministry of Science and Education of the Republic of Serbia : heart failure, myocardial and pericardial disease (2016-

2017)

Sibbing Dirk 1- Financial Declaration


- Astra Zeneca : Antiplatelets (2016-2017)

- Daiichi Sankyo : Antiplatelets (2016-2017)

- Eli Lilly : Antiplatelets (2016-2017)

- Bayer Healthcare : NAOCS (2016-2017)

- Pfizer : NOACS (2016-2017)

- Roche Diagnostics : Platelet function testing (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Roche Diagnostics : Platelets (2016-2017)

Sousa Uva Miguel


24/08/2018




8/54

Sousa Uva Miguel 1- Financial Declaration


- Boehringer-Ingelheim : Dabigatran (2016)


- Astra Zeneca : Ticagrelor (2016)

Stefanini Giulio 1- Financial Declaration


- Edwards Lifesciences : Interventional Cardiology (2016)

- Boston Scientific : Interventional Cardiology (2016-2017)

- B.Braun : Interventional Cardiology (2016-2017)

- Biosensors : Interventional cardiology (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : Interventional Cardiology (2016-2017)

Windecker Stephan 1- Financial Declaration


- Bayer AG : General Cardiology (2017)

- Abbott : Invasive Cardiology (2017)

- Boston Scientific : Invasive Cardiology (2017)

- Edwards Lifesciences : invasive Cardiology (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : General Cardiology (2016)

- Terumo Inc : General Cardiology (2016)

24/08/2018




9/54

Windecker Stephan - Bracco Pharmaceutical : General Cardiology (2016)

- Boston Scientific : General Cardiology (2016-2017)

- Abbott : General Cardiology (2017)

- St. Jude Medical : General Cardiology (2017)

- Amgen Inc. : General Cardiology (2017)

- Symetis SA : Invasive Cardiology (2017)

- Biotronik : Invasive Cardiology (2017)

- Terumo Inc : Invasive Cardiology (2017)

2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational

and Entreprenieur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)

Yadav Rashmi 1- Financial Declaration


- Medtronic : Advisory Board Fee (2017)

- Edwards Lifesciences : Speaker fees and consultancy (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Travel grants (flight, hotel and occasionally registration fee) from Maquet, Edwards and Medtronic to attend annual

meetings of professional societies such as EACTS, ISMICS, STS to the value of less than £10,000 (2016-2017)

Zembala Michael 1- Financial Declaration


- Symetis SA : TAVI valves - proctor for TA-TF (2016)

24/08/2018




10/54

Zembala Michael - Boston Scientific : TAVI valves - proctor for TA-TF (2017)


- Atricure : Proctor for AF ablation (2016-2017)

- Abbott : proctor for Heart Mate 3 LVAD (2017)

24/08/2018




11/54

Aboyans Victor 1- Financial Declaration


- Amgen : Hyperlipidemia (2017)

- Novartis : Hypertension (2017)

- Boehringer-Ingelheim : Oral anticoagulation (2017)

- Bayer Healthcare : Oral anticoagulation (2017)

- Pfizer/BMS alliance : Oral anticoagulation (2017)

Achenbach Stephan


Addad Faouzi


Agewall Stefan 1- Financial Declaration


- Astra Zeneca : Antiplatelet treatment (2017)

Akdemir Ramazan


Aladashvili Alexander


Andreotti Felicita 1- Financial Declaration


- Actelion : antiplatelet therapy (2017)

24/08/2018

2018 ESC/EACTS Guidelines on myocardial revascularization - Reviewers



12/54

Andreotti Felicita - Pfizer : apixaban (2017)


- Boehringer Ingelheim : dabigatran (2017)

- Amgen : dyslipidaemia (2017)

- Daiichi Sankyo : edoxaban (2017)

- Bayer Schering Pharma : rivaroxaban (2017)

- Medscape : stroke prevention in atrial fibrillation (2017)

Bajraktari Gani


Barbato Emanuele 1- Financial Declaration


- Boston Scientific : Education courses on rotational atherectomy (2017)

- Abbott Vascular : Educational courses on FFR (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Unrestricted grant for an investigator-driven study (2017)

Baumbach Andreas 1- Financial Declaration


- Astra Zeneca : Drugs (2017)

- Abiomed : LV Assist (2017)

- Abbott Vascular : Stents (2017)

- Microport : Stents (2017)

- Sinomed : Stents (2017)

24/08/2018




13/54

Baumbach Andreas B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Abbott Vascular : Stents (2017)

Becker David 1- Financial Declaration


- Pfizer : NOAC (2017)

- Merck Sharp & Dohme : NOAC (2017)


- Sanofi Aventis : PCSK9 I (2017)

Beleslin Branko 1- Financial Declaration

E - Research funding (personal).- Ministry of Science and Education of the Republic of Serbia : grant number 41022 (2017)

Brophy James


Bueno Hector 1- Financial Declaration


- Pfizer : Apixaban (2017)

- Bristol Myers Squibb : Apixaban (2017)

- Bayer : Aspirin, rivaroxaban (2017)

- MEDSCAPE-the heart.og : Inespecific (2017)

- Sanofi Aventis : PCSK9 inhibitors (2017)

- Novartis : Serelaxin, ACZ885, AHF Academy, (2017)


24/08/2018




14/54

Bueno Hector - Ferrer Internacional : Trinomia (polypill) (2017)



E - Research funding (personal).- BMS : CV013-011 - STANDUP-AHF trial (2017)

- Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017)

- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2017)

- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- VP elect. Spanish Society of Cardiology FAHA (2017)

Bunc Matjaz


Calvert Patrick Andrew 1- Financial Declaration


- Astra Zeneca : 2017 Acute Coronary Syndrome (Speaker at symposium) (2017)

- Sanofi Aventis : Alirocumab - single advisory board meeting 2016 (2017)

- Occlutech : Proctor for paravalvular leak closure 2017-8 (2017)

- St Jude Medical : Speaker at training meeting for structural heart disease 2016 (2017)

Capodanno Davide 1- Financial Declaration


- Bayer : Anticoagulant drugs (2017)

24/08/2018




15/54

Capodanno Davide - Daiichi Sankyo : Anticoagulant drugs (2017)

- Astra Zeneca : Antiplatelet drugs (2017)

- Abbott : Intravascular imaging (2017)

- Cordis : PCI (2017)

Chettibi Mohamed


Davierwala Piroze M


Delgado Victoria 1- Financial Declaration


- Abbott Vascular : Mitraclip (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : pacemakers (2017)

- Medtronic : pacemakers (2017)

- Biotronik : pacemakers (2017)

- Edwards Lifesciences : valves (2017)

Dudek Dariusz 1- Financial Declaration


- Medapp : shareholder (2017)

- Philips : speaker fee, advisory boards, investigator (2017)

- Sanofi Aventis : speaker fee, advisory boards, investigator (2017)

- TMS sp. z.o.o. : speaker fee, advisory boards, investigator (2017)

24/08/2018




16/54

Dudek Dariusz - Accord Healthcare : speaker fee, advisory boards, investigator (2017)

- Cardinal Health Poland Sp. z.o.o : speaker fee, advisory boards, investigator (2017)

- Medaccess : speaker fee, advisory boards, investigator (2017)

- Teleflex Polska Sp. z.o.o : speaker fee, advisory boards, investigator (2017)

- Astra Zeneca : speaker fee, advisory boards, investigator. (2017)

- Boston Scientific : speaker fee, advisory boards, investigator. (2017)

- Edwards Lifesciences : speaker fee, advisory boards, investigator. (2017)

- Medtronic : speaker fee, advisory boards, investigator. (2017)

- Biotronik : speaker fee, advisory boards, investigator. (2017)

- Terumo Inc : speaker fee, advisory boards, investigator. (2017)

- GE Healthcare : speaker fee, advisory boards, investigator. (2017)

- Bracco Pharmaceutical : speaker fee, advisory boards, investigator. (2017)

- Abbott Laboratories : speaker fee, advisory boards, investigator. (2017)

- Balton : speaker fee, advisory boards, investigator. (2017)

- Stentys : speaker fee, advisory boards, investigator. (2017)

- Comesa Polska : speaker fee, advisory boards, investigator. (2017)

- ProCardia Medical : speaker fee, advisory boards, investigator. (2017)

- SIS Medical : speaker fee, advisory boards, investigator. (2017)

- Aesculap Chifa : speaker fee, advisory boards, investigator. (2017)

24/08/2018




17/54

Duplyakov Dmitry 1- Financial Declaration


- Pfizer : apixaban (2017)


- Berlin Chemie AG : Ranolazine (2017)

- Bayer Healthcare : Rivaroxaban (2017)


Eftychiou Christos


Eha Jaan 1- Financial Declaration


- Astra Zeneca : simulators in cardiology, DAPT duration studies (2017)

Freemantle Nick 1- Financial Declaration


- University Hospitals NHS Foundation Trust : NHS Provider (2017)

E - Research funding (personal).- Allergan : Device (2017)

- Novo-Nordisk : Diabetes (2017)

- Sanofi Aventis : Diabetes, RA (2017)

- Takeda Pharmaceuticals : Oncology (2017)

- Ipsen : Oncology (2017)

- Biogen : RA (2017)

24/08/2018




18/54

Freemantle Nick 2- Other Positions of Influence

2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.- Honorary contract University Hospitals Birmingham NHS Foundation Trust, UK. (2017)

Funck-Brentano Christian 1- Financial Declaration


- Guerbet : Cardiac safety of a contrast agent (2017)

- Inventiva : Cardiac safety of a new chemical entity developed for systemic sclerosis (2017)

- Intracellular Therapies USA : Cardiac safety of an experimental non-cardiovascular drug (2017)

- Pierre-Fabre : Cardiac Safety of non-cardiovasclar products (2017)

- Janssen Belgium : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2017)

- MMV (CH) : Cardiac Saftey of two antimalarial drugs (2017)

- Actelion : Comments on the cardiac pharmacodynamic results of a phase I study of a new chemical entity (2017)

- Banook (CRO) : Data and Safety Monitoring Board for an antibody developed in rheumatology (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- Member of the Committee for Practice Guidelines - ESC (2006-2012) Member of the Task Force on the Guidelines on

Stable Coronary Artery Diseases (to be issued in 2019) (2017)

Gaemperli Oliver 1- Financial Declaration


- GE Healthcare : Imaging (2017)

Ghazzal Ziyad


24/08/2018




19/54

Gielen Stephan 1- Financial Declaration


- Astra Zeneca : antithrombotic therapy - advisory board membership, lecture honoraria (2017)

- Novartis : Heart failure therapy (lecture honoraria, travel support) (2017)

- Amgen Inc : PCSK9-inhibitors - lecture honoraria (2017)

- Daiichi Sankyo : Travel support for ESC congress participation (2017)


- Portola Pharmaceuticals : ANNEXA 4 Study - Dr. Härtel (2017)

- Biotronik : BIOWOMAN Study (2017)

- Daiichi Sankyo : ETNA-VTE Registry & EMIT-AF-VTE Registry - Dr. Härtel (2017)

- B. Braun : LOCOMOTIVE & CONSEQUENT ALL COMERS Registry (2017)

- CorVia : REDUCE LAP-HF TRIAL III/ Corvia Medical (2017)

- Amgen Inc : REPATHA Register - Dr. Härtel (2017)

- Novartis : Support for heart failure nurse training (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- National Coordinator for Prevention for Germany within the EAPC network Please Note: Research funding

(departmental or institutional) from healthcare industry is also listed under B. (2017)

Gilard Martine 1- Financial Declaration


- Bayer Healthcare : medication (2017)

- Medtronic : TAVI (2017)

24/08/2018




20/54

Gilard Martine B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Astra Zeneca : medication (2017)

- Terumo Inc : OCT/stent (2017)

- Abbott Vascular : Stent (2017)

- Edwards Lifesciences : TAVI (2017)

- GE Healthcare : Technology (2017)

Glineur David


Gorenek Bulent 1- Financial Declaration


- Bayer : Anticoagulation (2017)

- Daiichi Sankyo : Anticoagulation (2017)

- Pfizer : Anticoagulation (2017)

Gudnason Thorarinn


Haasenritter Joerg 2- Other Positions of Influence

2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- I am member of the German College of General Practitioners and Family Physicians and have been involved in the

devolpement of several German Guidelines: - Chest pain in primary care (http://www.awmf.org/leitlinien/detail/ll/053-023.html), - National Disease Management Guideline on stable coronary heart disease (http://www.leitlinien.de/nvl/khk), - Cardiovascular prevention in primary care (http://www.awmf.org/leitlinien/detail/anmeldung/1/ll/053-024.html). (2017)

24/08/2018




21/54

Haude Michael 1- Financial Declaration


- Lilly : anti platelet therapy (2017)

- Abbott : BVS, MitraClip (2017)

- Volcano : IVUS (2017)

- Biotronik : PCI (2017)

- Cardiac Dimensions : structual heart interventions (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Abbott : scaffold (2017)

- Biotronik : scaffold (2017)

- Cardiac Dimensions : structural heart intervention (2017)

Henderson Robert Anthony 1- Financial Declaration


- Creavo Medical Technologies : Novel technology to triage patients with chest pain in accident and emergency departments (2017)

24/08/2018




22/54

Henderson Robert Anthony 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Member, NICE Acute Coronary Syndromes Guideline Development Group, 2007-9 Clinical Advisor, NICE Stable Angina

Guideline Development Group, 2009-11 Member, NICE Stable Angina Topic Expert (Quality Standards) Group, 2011-2 Deputy Chair, NICE STEMI Guideline Development Group, 2011-3 Member, Advisory Group for Management of Stable Angina Evidence Update, 2012 (Evidence Update 23: Management of Stable Angina) Specialist Adviser to NICE Interventional Procedures Guidance Programme: Optical Coherence Tomography IPG481 2013; Patent Foramen Ovale 2013 IPG 472. Specialist committee member for acute coronary syndromes, NICE Quality Standard Advisory Committee (QSAC) 2013-14 Expert Adviser, NICE Medical Technologies Advisory Committee (MTAC) on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography, 2015-16. Topic Expert, NICE Surveillance report 2016 – Unstable angina and NSTEMI (2010) NICE guideline CG94 and Myocardial infarction with ST-segment elevation (2013) NICE guideline CG167. Expert Adviser, NICE Centre for Clinical Practice, 2016-19. Chair, Trial Steering Committee, FAMOUS-NSTEMI, 2012-8 Chair, Trial Steering Committee, ERIC-PPCI 2014-18 (2017)

Hofma Sjoerd H 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Abbott Vascular : cardiovascular (2017)

Ibanez Borja 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : I am Co-PI of a multicenter scientific grant for a study on behavioral change for primary prevention, NO

drugs or products involved. (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- My center (CNIC) is a non-profit organization that receives royalties for the sales of a polypill (trinomia) which is

constitued by aspirin-ramipril-simvastatin. I am not involved in the scientific development and have NO direct interest (no personal benefits). (2017)

Ibrahimov Firdovsi


24/08/2018




23/54

Infante de Oliveira Eduardo 1- Financial Declaration


- Terumo Inc : Coronary (2017)

- Medtronic : Coronary and non-coronary (2017)

- Boston Scientific : Left Atrial Appendage (2017)

- St Jude Medical : Left Atrial Appendage (2017)

- Abbott Vascular : Mitral Intervention (2017)

Iung Bernard 1- Financial Declaration


- Boehringer Ingelheim : Anticoagulants (2017)

- Novartis : Heart failure drugs (2017)

- Edwards Lifesciences : Heart valve prostheses (2017)

Jeger Raban 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- B.Braun : BASKET-SMALL 2 (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- Swiss Society of Cardiology Working Group Interventional Cardiology (2017)

Jeppsson Anders 1- Financial Declaration


- Astrazeneca : Cardiovascular (2017)

- LFB : Haemostasis (2017)

24/08/2018




24/54

Jeppsson Anders - Octapharma : Haemostasis (2017)

- CSL Behring : Haemotyasis (2017)

- XVIVO : Perfusion (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : Cardiovascular (2017)

Kala Petr 1- Financial Declaration


- Astra Zeneca : adjuvant pharmacology (2017)

- Boston Scientific : interventional cardiology (2017)

- Terumo Inc : interventional cardiology (2017)

- Amgen : research drug (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Zoll Medical : interventional cardiology (2017)

E - Research funding (personal).- Biosensors : interventional cardiology (2017)

Kanakakis Ioannis-Georgios



- Astra Zeneca : Antithrombotics (2017)

- Beringer : Antithrombotics (2017)

- Novartis : Heart failure (2017)

Katritsis Demosthenes 1- Financial Declaration

C - Receipt of royalties for intellectual property.- Oxford University Press : Cardiology Textbook (2017)

24/08/2018




25/54

Katritsis Demosthenes D - Research funding (departmental or institutional) from healthcare industry.- Medtonic : Electrophysiology (2017)

- Boston Scientific : Interventional Cardiology (2017)

Kedev Sasko 1- Financial Declaration


- Boston Scientific : Speaker fees (2017)

- Medtronic : Speaker fees (2017)

- Terumo Inc : Speaker fees (2017)

- Meril : Speaker fees (2017)

Kerimkulova Alina


Kibarskis Aleksandras


Knuuti Juhani 1- Financial Declaration


- Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017)

- GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)

Kolh Philippe H 1- Financial Declaration


- Astra Zeneca : Antiplatelet agents (2017)

Kovar Frantisek


24/08/2018




26/54

Leite-Moreira Adelino


Lund Lars 1- Financial Declaration


- Novartis : Heart Failure (2017)

- Sanofi Aventis : Heart Failure (2017)

- Astrazeneca : Heart Failure (2017)

- Viforpharma : Heart Failure (2017)


- Boehringer-Ingelheim : Heart Failure (2017)

- Novartis : Heart Failure (2017)

- Relypsa : Heart Failure (2017)

Magdy Ahmed


Maisano Francesco 1- Financial Declaration


- Perifect : Arrhythmias (2017)

- Transseptal Solutions : Arrhythmias (2017)

- 4Tech Cardio : Cardiotoracic Surgery (2017)

- Mitraltech : Cardiotoracic Surgery (2017)

- Xeltis : Valvular Heart Disease (2017)

24/08/2018




27/54

Maisano Francesco B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Abbott : Cardiotoracic Surgery (2017)

- Edwards Lifesciences : Cardiotoracic Surgery (2017)

- Medtronic : Cardiotoracic Surgery (2017)

- St. Jude : Cardiotoracic Surgery (2017)

C - Receipt of royalties for intellectual property.- Edwards Lifesciences : Cardiotoracic Surgery (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Edwards Lifesciences : Cardiovascular Surgery (2017)

- Medtronic : CoreValve (2017)

- Abbott : Mitraclip (2017)


2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.

- Healthcare - OTHER - 4Tech, Transeptal Solution, Mitraltech (2017)

Mehilli Julinda 1- Financial Declaration


- Daiichi Sankyo : coronary (2017)

- Biotronik : coronary (2017)

- Terumo Inc : coronary (2017)

- Abbott Vascular : coronary (2017)

- Bristol Myers Squibb : coronary (2017)

- Boston Scientific : structural (2017)

24/08/2018




28/54

Mehilli Julinda - Edwards Lifesciences : structural (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Abbott Vascular : coronary (2017)

- Edwards Lifesciences : structural (2017)

E - Research funding (personal).- DZHK : invasive cardiology (2017)

Metzler Bernhard


Montalescot Gilles 1- Financial Declaration


- Abbott : cardiovascular disease (2017)

- Amgen : cardiovascular disease (2017)

- Bayer : cardiovascular disease (2017)

- Boston Scientific : cardiovascular disease (2017)

- Medtronic : cardiovascular disease (2017)

- Pfizer : cardiovascular disease (2017)

- Servier : cardiovascular disease (2017)

- Actelion : cardiovascular disease (2017)

- Sanofi Aventis : cardiovascular disease (2017)

- Menarini : cardiovascular disease (2017)

- Lilly : cardiovascular disease (2017)

- WebMD : cardiovascular disease (2017)

24/08/2018




29/54

Montalescot Gilles - Cardiovascular Research Foundation : cardiovascular disease (2017)

- Europa : cardiovascular disease (2017)

- Lead-Up : cardiovascular disease (2017)

- Novo-Nordisk : cardiovascular disease (2017)

- Elsevier : cardiovascular disease (2017)

- MSD : cardiovascular disease (2017)

- American College of Cardiology : cardiovascular disease (2017)

- Astrazeneca : cardiovascular disease (2017)

- Daiichi-Sankyo : cardiovascular disease (2017)

- Boehringer Ingelheim : cardiovascular disease (2017)

- Bristol-Myers Squibb : cardiovascular disease (2017)

- Beth Israel Deaconess Medical : cardiovascular disease (2017)

- TIMI Study Group : cardiovascular disease (2017)

- Brigham Women's Hospital : cardiovascular disease (2017)

- The Mount Sinai School : cardiovascular disease (2017)


- Amgen : cardiovascular disease (2017)

- Bayer : cardiovascular disease (2017)

- Boehringer-Ingelheim : cardiovascular disease (2017)

- Pfizer : cardiovascular disease (2017)

- Sanofi Aventis : cardiovascular disease (2017)

24/08/2018




30/54

Montalescot Gilles - Bristol Myers Squibb : cardiovascular disease (2017)

- MSD : cardiovascular disease (2017)

- Astrazeneca : cardiovascular disease (2017)

- ICAN : cardiovascular disease (2017)

- Fédération Francaise de Cardiologie : cardiovascular disease (2017)

D - Research funding (departmental or institutional) from healthcare industry.- BMS : Apixaban (2017)

- Medtronic : Corevalve (2017)

- Bayer AG : Rivaroxaban (2017)


Mot Stefan


Motreff Pascal 1- Financial Declaration


- Abbott Vascular : BVS (2017)

- Terumo Inc : OCT imaging (2017)

- saint Jude medical : OCT imaging (2017)

Niemela Matti Jaakko


Ojeda Pinedo Soledad 1- Financial Declaration


- Spanish Society of Cardiology : Speaker fees (2017)

24/08/2018




31/54

Pagano Domenico 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Secretary General EACTS International Director Board Society Thoracic Surgeon ( US) (2017)

Parkhomenko Alexander 1- Financial Declaration


- BHFZ : corvitin (2017)

- Sanofi Aventis : enoxaparin (2017)

- Servier : preductal (2017)

- Bayer Healthcare : rivaroxaban (2017)

- Astra Zeneca : ticagrelor (2017)

D - Research funding (departmental or institutional) from healthcare industry.- European Research Foundation FP7 : European Research Foundation FP7 grant 2014-2017 (2017)

Peace Aaron J 1- Financial Declaration


- Pfizer : anticoagulation (2017)

- Bayer AG : anticoagulation (2017)

- Astra Zeneca : antiplatelet (2017)

- Daiichi Sankyo : antiplatelet and anticoagulation (2017)

- Biosensors : drug eluting stents and balloons (2017)

Pereira Bruno 1- Financial Declaration


- Merck Sharp & Dohme : Speaker fee (2017)

24/08/2018




32/54

Pereira Bruno - Menarini : Speaker fees (2017)

Petronio Anna Sonia 1- Financial Declaration


- Abbott : MitraClip (2017)

- Boston Scientific : TAVI (2017)

- Medtronic : TAVI (2017)

Piepoli Massimo Francesco


Popescu Bogdan Alexandru 1- Financial Declaration




2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- President-Elect of the Romanian Society of Cardiology (2017)

Postadzhiyan Arman 1- Financial Declaration


- Astra Zeneca : ACS (2017)

- Bayer : AF (2017)

- Boehringer-Ingelheim : AF (2017)

- Pfizer : AF, dyslipidemia (2017)

- Amgen : dyslipidemia (2017)

- Sanofi Aventis : dyslipidemia (2017)

24/08/2018




33/54

Roffi Marco 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : Stents (2017)

- Medtronic : Stents (2017)

- Biotronik : stents (2017)

- Terumo Inc : stents (2017)

- Abbott Vascular : stents (2017)

Romeo Francesco


Rudzitis Ainars 1- Financial Declaration


- Servier : Arterial Hypertension (2017)

- Berlin Menarini : CAD (2017)

- Shire HGT : Fabry disease (2017)

- Genzyme : Fabry disease (2017)

- Boehringer-Ingelheim : NOACs (2017)

Sadaba Rafael 1- Financial Declaration


- Atricure : AF ablation (2017)

D - Research funding (departmental or institutional) from healthcare industry.- TIGenix : Myocardial cell regeneration (2017)

24/08/2018




34/54

Shlyakhto Evgeny 1- Financial Declaration


- Krka Pharma : Arterial Hypertension (2017)

- Novartis : Arterial Hypertension, Heart Failure (2017)

- Merck Sharp & Dohme : Atherosclerosis (2017)

- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017)

- Pfizer : General Cardiology (2017)

Silber Sigmund


Simpson Iain A 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Member and Past President of the British Cardiovascular Society Member of the Management Board of the American

College of Cardiology National Cardiovascular Data Registries (2017)

Sisakian Hamayak 1- Financial Declaration


- Bayer : Rivaroxaban (2017)

- Servier : Trimetazidine, Ivabradine (2017)

Skoric Bosko 1- Financial Declaration


- Novartis : Entresto (2017)

Sparv David


24/08/2018




35/54

Steigen Terje Kristian


Stelmashok Valeriy 1- Financial Declaration


- Medtronic : Advisore boar team member (2017)

Tavilla Giuseppe


Terkelsen Christian Juhl 1- Financial Declaration


- Abiomed : impella (2017)

- Terumo Inc : Radial procedures (2017)

- Boston Scientific : rotational atherextomy (2017)

- Cardinal health : Sheatless procedures (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Terumo Inc : Coronary angiography equipment (2017)

Thiele Holger 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- European Research Foundation FP7 : Cardiogenic shock (2017)

Tousek Petr 1- Financial Declaration


- Astra Zeneca : Antiplatelet treatment (2017)

24/08/2018




36/54

Van Belle Eric 1- Financial Declaration


- Abbott : FFR (2017)

- Philips : FFR/iFR (2017)

Vranckx Pascal 1- Financial Declaration


- Daiichi Sankyo : Edoxaban (2017)

- Bayer Healthcare : Rivaroxaban (2017)


2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.

- Supplier (2017)

2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- Member of the Academic Research Consortium (2017)

Widimsky Petr 1- Financial Declaration


- Servier : Antiischemic agents (2017)

- Astra Zeneca : Antithrombotic agents (2017)

- Bayer : Antithrombotic agents (2017)

- Boehringer-Ingelheim : Antithrombotic agents (2017)


24/08/2018




37/54

Wijns William 1- Financial Declaration


- Biotronik : device (2017)

- Microport : device (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Microport : device (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Co-Director of Euro-PCR, the official annual meeting of EAPCI, since May 2010. Chairman of PCR, since May 2012. Co-

Director of PCR Africa, since February 2013. Non executive Board member and co-founder of Argonauts Partners (innovation accelerator). Please note that I have changed positions in 2016: Cardiovascular Center Aalst (Jan till April), sabbatical leave (May till September), NUIG as of October 2016. (2017)

Witkowski Adam 1- Financial Declaration


- Abbott Vascular : bioabsorbable coronary stents (2017)

- Terumo Inc : coronary stents (2017)

- Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI) (2017)

- Medtronic : Evolute aortic valves (TAVI) (2017)

- Edwards Lifesciences : Sapien aortic valves (TAVI) (2017)

Witt Nils


Xuereb Robert G


24/08/2018




38/54

Zamorano Gomez Jose Luis



- Bayer : afib (2017)

- Pfizer : Afib (2017)

Zavatta Marco 1- Financial Declaration


- Bayer Healthcare : Oral anticoagulants (2017)

24/08/2018




39/54

Aboyans Victor 1- Financial Declaration


- Amgen : Hyperlipidemia (2016-2017)

- Novartis : Hypertension (2016-2017)

- Boehringer-Ingelheim : Oral anticoagulation (2016-2017)

- Bayer Healthcare : Oral anticoagulation (2016-2017)

- Pfizer/BMS alliance : Oral anticoagulation (2016-2017)

Agewall Stefan 1- Financial Declaration


- Astra Zeneca : Antiplatelet treatment (2016-2017)

Barbato Emanuele 1- Financial Declaration


- St Jude Medical : Educational courses on FFR (2016)

- Boston Scientific : Education courses on rotational atherectomy (2016-2017)

- Abbott Vascular : Educational courses on FFR (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Unrestricted grant for an investigator-driven study (2016-2017)

Bueno Hector 1- Financial Declaration


- Abbott : BVS (2016)

- Servier : ivabradine (2016)

- Novartis : Serelaxin, ACZ885, AHF Academy (2016)

24/08/2018

ESC Committee for Practice Guidelines 2016-2018



40/54

Bueno Hector - Pfizer : Apixaban (2016-2017)

- Bristol Myers Squibb : Apixaban (2016-2017)

- Bayer : Aspirin, rivaroxaban (2016-2017)

- MEDSCAPE-the heart.og : Inespecific (2016-2017)

- Astra Zeneca : Ticagrelor (2016-2017)

- Ferrer Internacional : Trinomia (polypill) (2016-2017)

- Sanofi Aventis : PCSK9 inhibitors (2017)

- Novartis : Serelaxin, ACZ885, AHF Academy, (2017)



E - Research funding (personal).- Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016)

- BMS : CV013-011 - STANDUP-AHF trial (2016-2017)

- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016-2017)

- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016-2017)

- Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- FAHA (2016)

- VP elect. Spanish Society of Cardiology FAHA (2017)

24/08/2018




41/54

Coca Antonio 1- Financial Declaration


- Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016)

- Merck Serono : Bisoprolol-Amlodipine (2016-2017)

- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016-2017)

- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2016-2017)

Collet Jean-Philippe 1- Financial Declaration



- Sanofi Aventis : CLOPIDOGREL (2016)

- Medtronic : corevalve (2016)


- Astra-Zeneca : ticagrelor (2016)

- MSD : VORAPAXAR (2016)

- Bayer Healthcare : xarelto (2016)

- Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017)

- Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017)

- Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017)

- Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bristol Myers Squibb : APIXABAN (2016)

- Medtronic : COREVALVE (2016)

24/08/2018




42/54

Collet Jean-Philippe - Stago : LABORATORY TEST (2016)


- FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)

- ICAN : THROMBOSIS (2016)

- Astra Zeneca : TICAGRELOR (2016)

- Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017)

- Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017)

- Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017)

- Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

- Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

Coman Ioan Mircea 1- Financial Declaration


- Daiichi Sankyo : anticoagulants (2016-2017)

- Johnson & Johnson : antithrombotic (2016-2017)

- Bayer AG : antithrombotic (2016-2017)

- Sanofi Aventis : dyslipidemia (2016-2017)

- Fournier Laboratories : dyslipidemia (2016-2017)

- Amgen Inc : dyslipidemia , (2016-2017)

- Novartis : HF (2016-2017)

24/08/2018




43/54

Coman Ioan Mircea - Vifor International : iron deficiency (2016-2017)

- Actelion : PHT (2016-2017)


- Daiichi Sankyo : anticoagulants (2016-2017)

- Johnson & Johnson : antithrombotic (2016-2017)

- Bayer AG : antithrombotic (2016-2017)

- Sanofi Aventis : dyslipidemia (2016-2017)

- Amgen Inc : dyslipidemia (2016-2017)

- Fournier Laboratories : dyslipidemia (2016-2017)

- Novartis : HF (2016-2017)

- Vifor International : iron deficiency (2016-2017)

- Actelion : PHT (2016-2017)

Delgado Victoria 1- Financial Declaration


- Abbott Vascular : Mitraclip (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : Pacemaker-Heart failure (2016)

- Medtronic : Pacemaker-Heart failure (2016)

- Biotronik : Pacemaker-Heart Failure (2016)

- Edwards Lifesciences : Valvular heart disease (2016)

- Boston Scientific : pacemakers (2017)

- Medtronic : pacemakers (2017)

24/08/2018




44/54

Delgado Victoria - Biotronik : pacemakers (2017)

- Edwards Lifesciences : valves (2017)

Fitzsimons Donna


Gaemperli Oliver 1- Financial Declaration


- GE-Healthcare : Imaging (2016)

- Amgen Inc : PCSK9 (2016)

- Servier : Procorolan (2016)


Hindricks Gerhard 1- Financial Declaration


- Boston Scientific : CIEDs and interventional electrophysiology (2016)

- St Jude Medical : CIEDs and interventional electrophysiology (2016)

- Biotronik : CIEDs and interventional electrophysiology (2016)

- Abbott : Pacemaker, Ablation (2017)

- Biosense Webster : Pacemaker, Ablation (2017)

- Biotronik : Pacemaker, catheter (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : CIEDs and interventional electrophysiology (2016)

- St Jude Medical : CIEDs and interventional electrophysiology (2016)

- Abbott, Biotronik, Medtronic, Boston Scientific : Electropyhsiology, arrhythmias (2017)

24/08/2018




45/54

Hindricks Gerhard 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the

Helios Hospital Group. (2017)

Iung Bernard 1- Financial Declaration


- Edwards Lifesciences : Heart Valve Prostheses (2016-2017)

- Boehringer Ingelheim : Anticoagulants (2017)

- Novartis : Heart failure drugs (2017)

Juni Peter



D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : Anti-platelet Therapy (2017)

- Biotronik : Drug-eluting stents (2017)

- Biosensors International Group : Drug-eluting stents (2017)

- The Medicines Company : Thrombin inhibitors (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly

and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

24/08/2018




46/54

Katus Hugo 1- Financial Declaration


- Daiichi Sankyo : Lixiana_NOAK (2016-2017)


- Bayer Vital : Xarelto-NOAK (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Biobank (2016-2017)

- Philips : MRT (2016-2017)

Knuuti Juhani 1- Financial Declaration


- Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017)

- GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Orion : Brain diseases (2016)

- AC Immune : Brain diseses (2016)

- Antaros : Endocrinology (2016)

- Boehringer-Ingelheim : Neurology (2016)

- MSD : Neurology (2016)

- GE Gealthcare : Neurology (2016)

Lancellotti Patrizio 1- Financial Declaration


- St Jude Medical : Echo course (2016)

24/08/2018




47/54

Lancellotti Patrizio - Servier : Ischemic Heart Disease (2016-2017)


- Medtronic : Structural disease (2016)

- Bayer : NOAC (2016-2017)

Leclercq Christophe 1- Financial Declaration


- Sorin Group : devices (2016)

- St Jude Medical : devices (2016)

- Bayer Healthcare : DOAC (2016)

- Boston Scientific : devices (2016-2017)

- Medtronic : devices (2016-2017)

- Biotronik : devices (2016-2017)

- Abbott : devices (2017)

- LIvanova : devices (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Biotronik : devices (2017)

McDonagh Theresa 1- Financial Declaration


- Vifor International : Ferrinject (2016-2017)

- Novartis : Honoraria (2016-2017)

- Bayer AG : Honoraria (2017)

24/08/2018




48/54

Piepoli Massimo Francesco




- Servier : Committee member, Speaker fee (2016)

- Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016)

- Amgen : Metabolic, Lipid (2016)


- Novartis : Heart Failure Prevention Initiatives (2016)

Ponikowski Piotr 1- Financial Declaration


- Abbott Vascular : devices (2016)

- BioControl : devices (2016)

- Pfizer : lipids (2016)

- Boehringer-Ingelheim : anticoagulant, diabetes (2016-2017)

- Respicardia : devices (2016-2017)

- Novartis : heart failure (2016-2017)

- Cardiorentis : heart failure (2016-2017)

- Berlin Chemie AG : heart failure (2016-2017)

- Bayer Healthcare : heart failure (2016-2017)

- Vifor Pharma ltd : heart failure (2016-2017)

24/08/2018




49/54

Ponikowski Piotr - CIBIEM : heart failure (2016-2017)

- Servier : heart failure, coronary artery disease (2016-2017)

- Amgen : heart failure, lipids (2016-2017)

- Pfizer : lipids, heart failure (2017)


- DC Device : devices (2016)

- Cardiorentis : heart failure (2016)

- Respicardia : anticoagulant (2016-2017)

- BioControl : devices (2016-2017)

- Novartis : heart failure (2016-2017)

- Bayer Healthcare : heart failure (2016-2017)

- CIBIEM : heart failure (2016-2017)

- Servier : heart failure, coronary artery disease (2016-2017)

- Amgen : heart failure, lipids (2016-2017)

- Cardionomic : devices (2017)

- Impuls Dynamics : devices (2017)

- National Institute of Health : heart failure (2017)

- European Union grant : heart failure, prevention (2017)

Richter Dimitrios 1- Financial Declaration


- Angelini : Lipids (2016)

24/08/2018




50/54

Richter Dimitrios - Swisspharma : lipids-hypertension (2016)

- Astra Zeneca : lipids-thrombosis (2016)

- Pfizer : lipids-thrombosis (2016)

- Winmedica : lipids-thrombosis (2016)

- Boehringer-Ingelheim : thrombosis (2016)

- Menarini : CAD- hypertension (2016-2017)

- Novartis : hypertension (2016-2017)

- Abbott : lipids (2016-2017)

- Amgen : lipids (2016-2017)

- Sanofi Aventis : Lipids (2016-2017)

- Lilly : Lipids (2016-2017)

- Unilever : lipids (2016-2017)

- Merck Sharp & Dohme : lipids (2016-2017)

- Vianex : lipids (2016-2017)

- Galenica : Lipids (2016-2017)

- Teva Pharmaceutical Industries : lipids, hypertension (2016-2017)

- Bayer Healthcare : Thrombosis (2016-2017)

- Edwards Lifesciences : aortic stenosis (2017)

- Novo-Nordisk : diabetes (2017)

- Unipharma : hypertension-thrombosis (2017)

24/08/2018




51/54

Roffi Marco 1- Financial Declaration


- Terumo Inc : coronary catheters (2016)

- Johnson & Johnson : coronary catheters (2016)

- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : devices (2016)

- Medtronic : devices (2016)

- Biotronik : devices (2016)

- Terumo Inc : devices (2016)

- Abbott Vascular : devices (2016)

- Boston Scientific : Stents (2017)


- Biotronik : stents (2017)

- Terumo Inc : stents (2017)

- Abbott Vascular : stents (2017)

Shlyakhto Evgeny 1- Financial Declaration


- Krka Pharma : Arterial Hypertension (2016-2017)

- Novartis : Arterial Hypertension, Heart Failure (2016-2017)

- Merck Sharp & Dohme : Atherosclerosis (2016-2017)

- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016-2017)

24/08/2018




52/54

Shlyakhto Evgeny - Pfizer : General Cardiology (2016-2017)

Simpson Iain A 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Member and Past President of the British Cardiovascular Society Member of the Management Board of the American

College of Cardiology National Cardiovascular Data Registries (2016-2017)

Sousa Uva Miguel







Windecker Stephan 1- Financial Declaration


- Bayer AG : General Cardiology (2017)

- Abbott : Invasive Cardiology (2017)

- Boston Scientific : Invasive Cardiology (2017)

- Edwards Lifesciences : invasive Cardiology (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : General Cardiology (2016)

- Terumo Inc : General Cardiology (2016)

- Bracco Pharmaceutical : General Cardiology (2016)

- Boston Scientific : General Cardiology (2016-2017)

24/08/2018




53/54

Windecker Stephan - Abbott : General Cardiology (2017)

- St. Jude Medical : General Cardiology (2017)

- Amgen Inc. : General Cardiology (2017)

- Symetis SA : Invasive Cardiology (2017)

- Biotronik : Invasive Cardiology (2017)

- Terumo Inc : Invasive Cardiology (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational

and Entreprenieur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)

Zamorano Gomez Jose Luis



- Philips : 3D Echocardiography. (2016)

- Servier : Clinical case presentation during ESC Cong 2016 (2016)

- Pfizer : speaker CV risk factors. (2016)

- MSD : speaker. CV risk factors (2016)

- Bayer : afib (2017)

- Pfizer : Afib (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016)

- Abbott : Epidemiology study of Mitral regurgitation (2016)

24/08/2018




54/54

2018 esc/eacts guidelines on myocardial revascularization ... · benedetto umberto nothing to be...

Documents